Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Acute Encephalopathy is associated with worse outcomes in COVID-19 patients
Infectious Disease
Infectious Disease Posters (7:00 AM-5:00 PM)
006
To determine prevalence of acute encephalopathy in hospitalized COVID-19 patients and to determine outcomes compared to those without acute encephalopathy.
Acute encephalopathy in the setting of any infection is associated with severity of the disease process. With this COVID-19 pandemic, we did not find any studies to associate the development of acute encephalopathy with outcomes in hospitalized COVID-19 patients.
This was a retrospective cohort study where we examined clinical outcome parameters comprising ‘need for critical care services’, ‘intubation’ and ’30-day mortality’ among hospitalized COVID-19 patients with and without acute encephalopathy, before and after propensity-score matching. TriNetX, which is a large global COVID-19 database was used to obtain medical record data and their analytics function was used for statistical analysis.
Of 12,601 hospitalized COVID-19 patients, 1092 (8.7%) developed acute encephalopathy. Patients in the acute encephalopathy group were older (67 vs. 61 years) and had higher prevalence of medical co-morbidities including obesity, hypertension, diabetes, heart disease, COPD, chronic kidney and liver disease among others. Before and after propensity score matching for co-morbidities, patients with acute encephalopathy were more likely to need critical care services (35.6% vs. 16.9%, p < 0.0001), intubation (19.5% vs. 6.0%, p < 0.0001) and had a higher 30-day mortality (24.3% vs. 17.9%, p 0.0002).
Among hospitalized COVID-19 patients, acute encephalopathy is common and more likely to occur in patients with medical co-morbidities and are more likely to need critical care, intubation and have a higher 30-day mortality even after adjusting for age and underlying medical co-morbidities.
Authors/Disclosures
Narenraj Arulprakash, MD (Baptist Health)
PRESENTER 		Dr. Arulprakash has nothing to disclose.
Krishna Nalleballe, MD, FÂ鶹´«Ã½Ó³»­ Dr. Nalleballe has nothing to disclose.
Sanjeeva R. Onteddu, MD, FÂ鶹´«Ã½Ó³»­ (UAMS) Dr. Onteddu has nothing to disclose.
Mhd Ezzat Zaghlouleh, MD (Department of Neurology The Ohio State University) Dr. Zaghlouleh has nothing to disclose.
Vishank A. Shah, MD (Johns Hopkins University) Dr. Shah has nothing to disclose.